Pfizer receives Priority Review for Dacomitinib in NSCLC

Pfizer Inc. (NYSE:PFE) said FDA accepted and granted Priority Review to an NDA for dacomitinib (PF-00299804) to treat advanced or metastatic EGFR mutation-positive non-small cell lung cancer in treatment-naïve patients. The PDUFA date is in September.

Pfizer also said on April 4 that EMA accepted an MAA for the pan-human EGFR tyrosine kinase inhibitor (TKI) for the same indication...